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Background and Aims: Interstitial lung disease is a rare presentation of juvenile idiopathic arthritis. There are a few reports of patients with JIA induced ILD including this case.
Methods: This 10 years old girl got admitted in our hospital on October, 2017. She was diagnosed as a case of polyarticular, RA positive JIA seven years back. She was treated then with injection methotrexate, tablet leflunomide, tablet prednisolone. After 3 months, she developed fever and cough for which she was diagnosed as a case of pulmonary tuberculosis. She was treated with paediatric anti-TB regimen for six months. For the last one year, she developed exertional shortness of breath and productive cough. On examination, the girl was ill-looking with puffy face, mildly anaemic, clubbing present, respiratory rate 34 breaths per minute. Chest examination shows symmetrically diminished chest movement. There was bilateral diffuse end-inspiratory fine crepitation unaltered with coughing.
CVS examination showed features of pulmonary hypertension.
Results: Investigation showed haemoglobin% 9.5 g/dl, ESR 40 mm in 1 st hour, sputum for AFB and GeneXpert were negative. Chest X-ray PA view showed bilateral diffuse reticulonodular opacities with enlarged cardiac shadow. Echocardiography showed features of corpulmonale and HRCT chest findings include reticulo-nodular opacities in all lobes of both lungs. Finally the patient was diagnosed as a case of JIA induced ILD with Corpulmonale. Then she was treated with oxygen inhalation, injection methylprednisolone, tablet pirfenidone, tab N-acetylcysteine. But the patient did not improve and later developed respiratory failure and was shifted to ICU. Ultimately she died. Background and Aims: Pulmonary embolism (PE) is a global health issue. Recent years, the incidence, mortality, and disease burden of PE dramatically increase along with the social aging, awareness of the disease and diagnosis technique advances in China. In order to provide the latest nationwide data in PE, we initiated a prospective, multicentre and ongoing registry study on PE since Jan 2008, which is the China Pulmonary Thromboembolism Registry Study (CURES).
Conclusion

Methods:
The CURES is a three-stage designed study, recruiting adult patients presenting with symptomatic PE alone or PE with deep venous thrombosis (DVT) confirmed by objective tests. Stage I of the study started from Jan 2008 to Jun 2011, and consecutively enrolled about 3000 eligible PE or PE with DVT patients. Stage II continued to enrol about 5,000 patients with three month follow-up between Jul 2011 and Jul 2016. Stage III started from Aug 2016 and expected to last until Dec 2019, intending to further recruit 3000 patients with regular follow-up visit every three months. In the meanwhile, blood samples were also collected in Stage III to investigate thromboembolism relevant genetic susceptibility and potential biomarkers. Demographic data, medical history, risk factors of the disease, symptoms and signs on presentation, diagnostic methods and results, treatment options and clinical outcomes were collected. All patients provided written consent to their participation.
Results: Until now, the CURES study has included over 10,000 PE or PE with DVT patients from 94 medical centres from the China PE-DVT network. The collected data could be further analyzed and reveal epidemiological characteristics, patterns of clinical care and outcomes of the disease in the real-world setting.
Conclusion: CURES is the largest prospective multicentre registry study on PE in China, which provides us valuable data and insights into the disease, and achieves the ultimate goal of improving disease control and management. contribute to the pathogenesis of pulmonary hypertension (PH). Therapy with hydrogen gas is reported to have both anti-oxidant and antiinflammatory effects in various diseases, yet whether and how inhaled hydrogen gas affects the pathogenesis of PH is unclear.
Methods: Hydrogen gas inhalation was given to experimental rat model of PH induced by monocrotaline (MCT) injection at two time point:
(1) immediately after MCT injection (prevention model); (2) 16 days after MCT injection (treatment model). The parameters indicating development of PH; right ventricular systolic pressure (RVSP), right ventricle weight, and right ventricular hypertrophy index Results: For mice received hydrogen immediately after MCT injection, hydrogen gas inhalation significantly reduced RSVP, right ventricle weight, and right ventricle hypertrophy. Increased production of IL6 and malondialdehyde (MDA) were found in lung tissues and plasma from rats injected with MCT, these parameters were abrogated in those receiving hydrogen gas inhalation. Anti-inflammatory effects were also indicated by less macrophage infiltration in lungs from rats receiving hydrogen gas inhalation. Furthermore, in cultured rat pulmonary arterial smooth muscle cells (PASMCs), hydrogen gas prevented IL-6 secretion induced by hydrogen peroxide. In lung tissues from MCT-injected rats and hydrogen peroxide (H 2 O 2 ) treated PASMCs, hydrogen gas up-regulated the levels of nuclear factor-erythroid 2-related factor 2 (Nrf2) and its target protein 
